Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836625 | 0.84 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL19346347 | 0.84 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL2825786 | 0.84 | ALDH1A1 (0.62) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL11222668 | 0.80 | ALDH1A1 (0.75) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL13614102 | 0.80 | MEN1 (0.57) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL3527141 | 0.79 | ALDH1A1 (0.70) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| Sulfosalicylic SCHEMBL29364125 | 0.79 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| Sulfosalicylic SCHEMBL6717073 | 0.79 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| Sulfosalicylic SCHEMBL34766 | 0.79 | ALDH1A1 (0.96) | ALDH1A1KDM4EHSD17B10HPGDMEN1 | |
| SCHEMBL3504223 | 0.79 | ALDH1A1 (0.65) | ALDH1A1KDM4EHSD17B10HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11083704-B2 | Method of administering nitroxyl donating compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190343790-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | CARDIOXYL PHARMACEUTICALS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018128999-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| CN-105142627-A | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS INC | 2015-12-09 | — | — | CN | disclosed |
| EP-2945621-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113700-A9 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014113700-A9 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014113700-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113700-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | ALDH1A1 954/4885KDM4E 1476/4885HSD17B10 418/4885 |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | ALDH1A1 954/4885KDM4E 1476/4885HSD17B10 418/4885 |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | ALDH1A1 954/4885KDM4E 1476/4885HSD17B10 418/4885 |
| US-11083704-B2 | Method of administering nitroxyl donating compounds | NQO1, UGT1A3, NNMT | ALDH1A1 513/4885KDM4E 1603/4885HSD17B10 712/4885 |
| US-20190343790-A1 | METHOD OF ADMINISTERING NITROXYL DONATING COMPOUNDS | NQO1, UGT1A3, NNMT | ALDH1A1 513/4885KDM4E 1603/4885HSD17B10 712/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | ALDH1A1 954/4885KDM4E 1476/4885HSD17B10 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.